STereotactic Arrhythmia Radioablation (STAR): the Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary consortium (STOPSTORM.eu) and review of current patterns of STAR practice in Europe
EP Europace Journal

Abstract
The EU Horizon 2020 Framework-funded Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary (STOPSTORM) consortium has been established as a large research network for investigating STereotactic Arrhythmia Radioablation (STAR) for ventricular tachycardia (VT). The aim is to provide a pooled treatment database to evaluate patterns of practice and outcomes of STAR and finally to harmonize STAR within Europe. The consortium comprises 31 clinical and research institutions. The project is divided into nine work packages (WPs): (i) observational cohort; (ii) standardization and harmonization of target delineation; (iii) harmonized prospective cohort; (iv) quality assurance (QA); (v) analysis and evaluation; (vi, ix) ethics and regulations; and (vii, viii) project coordination and dissemination. To provide a review of current clinical STAR practice in Europe, a comprehensive questionnaire was performed at project start. The STOPSTORM Institutions’ experience in VT catheter ablation (83% ≥ 20 ann.) and stereotactic body radiotherapy (59% > 200 ann.) was adequate, and 84 STAR treatments were performed until project launch, while 8/22 centres already recruited VT patients in national clinical trials. The majority currently base their target definition on mapping during VT (96%) and/or pace mapping (75%), reduced voltage areas (63%), or late ventricular potentials (75%) during sinus rhythm. The majority currently apply a single-fraction dose of 25 Gy while planning techniques and dose prescription methods vary greatly. The current clinical STAR practice in the STOPSTORM consortium highlights potential areas of optimization and harmonization for substrate mapping, target delineation, motion management, dosimetry, and QA, which will be addressed in the various WPs.
Contributors

Esther G C Troost
Author

Viviana Vitolo
Author

Nicolaus Andratschke
Author

Katja Zeppenfeld
Author

Slawomir Blamek
Author

Martin Fast
Author

Ludovica de Panfilis
Author

Oliver Blanck
Author

Stefano Mandija
Author

Marcin Miszczyk
Author

David Krug
Author

Bartłomiej Tomasik
Author

Joost J C Verhoeff
Author

Kristine E Stickney
Author

Pino Alcantara
Author

Filippo Alongi
Author

Ricardo Salgado Aranda
Author

Brian V Balgobind
Author

Judit Boda-Heggemann
Author

Leif-Hendrik Boldt
Author

Nicola Bottoni
Author

Jakub Cvek
Author

Olgun Elicin
Author

Gaetano Maria De Ferrari
Author

Rutger J Hassink
Author

Colien Hazelaar
Author

Gerhard Hindricks
Author

Coen Hurkmans
Author

Cinzia Iotti
Author

Tomasz Jadczyk
Author

Raphaël Jumeau
Author

Steen Buus Kristiansen
Author

Manuel Algara López
Author

Felix Mehrhof
Author

Ditte Sloth Møller
Author

Alexandre Ouss
Author

Jiri Plasek
Author

Tobias Reichlin
Author

Ardan M Saguner
Author

Rachel M A ter Bekke
Author
Cardiovascular Research Institute Maastricht (CARIM) Maastricht , Netherlands (The)

José López Torrecilla
Author
You may be interested in












